Merck asks EMA to reevaluate rejected Covid-19 antiviral

Merck is seeking a reevaluation of the European Medicines Agency’s (EMA) rejection of the pharma’s blockbuster Covid-19 pill, known as Lagevrio (molnupiravir), which has served as a second option to Pfizer’s Paxlovid (nirmatrelvir/ritonavir).